In today’s briefing:
- Agilent Technologies: Pharma Market Expansion As A Key Growth Catalyst! – Major Drivers
- Japan Lifeline Co., Ltd (7575 JP): Research Update
- ARWR: License and Collaboration Deal with Sarepta Includes 825 Million Upon Closing
- BLRX: Ayrmid Assumes Commercialization Efforts
- LNTH: Initiating Coverage – A Glowing Recommendation
- TNXP: NDA Filed for TNX-102 SL in Fibromyalgia
Agilent Technologies: Pharma Market Expansion As A Key Growth Catalyst! – Major Drivers
- Agilent Technologies, Inc. recently reported its fourth quarter results for fiscal year 2024.
- The company generated revenues of $1.701 billion, marking roughly 1% growth in reported figures, with core growth remaining flat despite challenging market conditions.
- Notably, Agilent’s total company book-to-bill ratio exceeded one, indicating a steady market recovery and positioning for continued improvement into 2025.
Japan Lifeline Co., Ltd (7575 JP): Research Update
- Japan Lifeline [JLL] produced historical semi-annual earnings with FY24 1H OP of ¥6,260mil (+14.4% YoY) on sales of ¥27,985mil (+11.4% YoY), which landed above expectation.
- Despite this robust performance, JLL has not revised its full-year FY24 guidance as the 2H presents with several potential earnings risks such as 1) fewer operating days, which will impact device sales, 2) an increase in outsourced products reducing GPM, 3) the possibility of a change in the competitive landscape for one of JLL’s core products.
- The company’s shareholder return policy is the higher of (1) a pay-out ratio of 40% or (2) a Dividend on Equity [DOE] of 5%.
ARWR: License and Collaboration Deal with Sarepta Includes 825 Million Upon Closing
- On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) in which Arrowhead will receive $825 million on closing, consisting of a $500 million upfront payment and $325 million as an equity investment priced at a 35% premium.
- The agreement includes four clinical stage products (ARO-DUX4, ARO-DM1, ARO-MMP7, ARO-ATXN2), three preclinical programs (ARO-HTT, ARO-ATXN1, ARO-ATXN3), and during the five-year term of the agreement Sarepta can propose up to six new CNS or muscle targets, with Arrowhead responsible for discovery and preclinical development.
- This deal further validates Arrowheads technology and provides capital to fund operations into 2028.
BLRX: Ayrmid Assumes Commercialization Efforts
- BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting indications in stem cell mobilization (SCM) & in the treatment of advanced pancreatic cancer.
- The candidate is approved in the US for SCM and is undergoing studies for use in gene therapy and in pancreatic cancer.
- Partner Gloria Biosciences is developing motixafortide in Asia & is expected to be conducting bridging studies in the near term for SCM & longer-term studies for other indications.
LNTH: Initiating Coverage – A Glowing Recommendation
- Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics.
- It offers a portfolio of diagnostic & therapeutic products directly & via partnerships & licensing.
- The primary revenue driver is Pylarify, a PET tracer for PSMA-expressing prostate cancer.
TNXP: NDA Filed for TNX-102 SL in Fibromyalgia
- On October 16, 2024, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it submitted the New Drug Application (NDA) for TNX-102 SL for the treatment of fibromyalgia.
- The NDA is supported by the results of two Phase 3 clinical trials that reported statistically significant results on the primary endpoint of reducing widespread pain.
- The FDA typically has a 60-day filing review period to determine whether the submitted NDA is acceptable for review.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
